BOLDBoundless Bio Inc. Common Stock

3.000USD+4.90%Mkt Cap: 68.24M $P/E:

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940,…